Glaxo's OTC Flonase push delivers almost $100M so far; J&J settles a Risperdal breast-growth suit;

@FiercePharma: ICYMI: Look for orphan drugs to keep fueling M&A, Moody's says. Report | Follow @FiercePharma

@CarlyHFierce: Valeant plots big DTC push for Xifaxan while rival Actavis drug waits on DEA. More from FiercePharmaMarketing | Follow @CarlyHFierce

> GlaxoSmithKline's ($GSK) marketing blitz on the newly OTC allergy remedy Flonase has paid off, with almost $100 million in sales during its first 16 weeks on the market. Report

> Two U.S. Senators, concerned that compounding pharmacy rules would restrict use of Roche's ($RHHBY) cancer drug Avastin as a substitute for its pricier eye treatment Lucentis, have written HHS to raise the question. Report

> Johnson & Johnson ($JNJ) settled another lawsuit over Risperdal's potential to trigger breast development in boys for an undisclosed sum; two other suits have ended in decisions against J&J--at least partly--but lawyers say the litigation will continue case by case. Report

> The FDA gave priority review to Merck & Co.'s ($MRK) Keytruda as a treatment for non-small cell lung cancer, advancing the drug in its race to compete with Bristol-Myers Squibb's ($BMY) Opdivo in that disease. Report

> Novartis ($NVS) said new one-year data for its anti-inflammatory drug Cosentyx in ankylosing spondylitis will be presented at the upcoming European League Against Rheumatism meeting. Report

Medical Device News

@FierceMedDev: ICYMI: Fierce exclusive: Zimmer to cut staff, close its dental headquarters following $13B merger with Biomet. Report | Follow @FierceMedDev

@VarunSaxena2: Hospitals tell feds that they can do more to support unique device ID. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: Otsuka faces the music for generic Abilify, loses battle with | Follow @EmilyWFierce

> Prenatal Dx player Natera looks to do an up to $100M IPO to expand, move into liquid biopsy. More

> Israeli startup unveils cloud-based mobile fetal monitor. Article

Biotech News

@FierceBiotech: ICYMI yesterday: Bristol-Myers fires off a lawsuit to sideline R&D defector headed to rival AstraZeneca. Article | Follow @FierceBiotech

@JohnCFierce: Top #ASCO15 story for @FierceBiotech: Genentech's PD-L1 breakthrough star 'atezo' positioned to vault ahead on cancer. Story | Follow @JohnCFierce

@DamianFierce: Kinda feels like $JUNO Googled "CAR-T" and is gradually buying the whole first page of results. Release | Story | Follow @DamianFierce

> Regulus tanks on CEO's exit as investors fear a bad omen. Article

> Sprout's 'female Viagra' lines up for a make-or-break FDA review. Report

> With a crucial CAR-T trial looming for Cellectis, a confident André Choulika is laying it all on the line. Article

Drug Delivery News

> NeuroVive's cardiology candidate fails to meet its endpoint. Item

> Cedars-Sinai team develops delivery-Dx combo nanomed for brain cancer. More

> Reassessment of trial data at ASCO to benefit Sirtex's cancer-fighting microspheres. Report

> Novartis partners with 'robotic' pillmaker in oral biologic race. Story

> FDA approves Lilly's reformulated insulin to foster patient convenience. Article

Pharma Manufacturing News

> Myanmar Pharma plans $30M upgrade to compete with Indian imports. Item

> South Korea's Green Cross building $240M plasma plant in Canada. More

> Hospira again shipping ketorolac but U.S. faces many drug shortages. Story

> Wockhardt looks to get banned plants back online in 2016. Article

> Sources: Cipla, Lupin bid on UCB's Kremers Urban. Report

Pharma Asia News

> Leading Japan drug firms team up with AZ on parasitic disease research. News

> SK Biopharmaceuticals says Jazz-led sleep disorder PhIII candidate on the cards. Report

> Taiwan recalls Y.F. Chemical sodium chloride products on new contamination events. Article

> Cipla, Lupin in UCB U.S. generics bid as India-linked M&A heats up. More

> Novartis India gets reprieve from NPPA on fine for over-pricing drug. Story

> And Finally... Medicare paid doctors $90 billion in 2013, up 17%. Report

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.